Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients

Lancet

Volumn 347, Issue 8998, 1996, Pages 353-357

  Schmitz, N ^a   Linch, D C ^b   Dreger, P ^a   Goldstone, A H ^b   Boogaerts, M A ^c   Ferrant, A ^d   Demuynck, H M S ^c   Link, H ^f   Zander, A ^e   Barge, A ^g   Borkett, K ^g  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^c Department of Haematology   (Belgium)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e UNIVERSITY OF HAMBURG   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g AMGEN LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYTARABINE; ETOPOSIDE; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW CELL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; HEMATOPOIETIC STEM CELL; HODGKIN DISEASE; HOSPITALIZATION; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKAPHERESIS; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; NEUTROPHIL; NONHODGKIN LYMPHOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL; THROMBOCYTE TRANSFUSION;

EID: 9044236159     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)90536-X     Document Type: Article

References (26)

1. Goodman JW, Hodgson GS. Evidence for stem cells in the peripheral blood of mice. Blood 1962; 19: 702-14.
2. McCredie KB, Hersh EM, Freireich EJ. Cells capable of colony formation in the peripheral blood of man. Science 1971; 171: 293-94.
3. Körbling M, Dörken B, Ho AD, Pezzutto A, Hunstein W, Fliedner TM. Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. Blood 1986; 67: 529-32.
4. Kessinger A, Armitage JO, Landmark JD, Smith DM, Weisenberger DD. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 1988; 71: 723-27.
5. Schmitz N, Dreger P, Suttorp M, et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-72.
6. Bishop MR, Anderson JR, Jackson JD, et al. High-dose therapy and peripheral blood progenitor cell transplantation: effects of recombinant human granulocyte-macrophage colony-stimulating factor on the graft. Blood 1994; 83: 610-16.
7. Richman CM, Weiner RS, Yankee RA. Increase in circulating stem cells following chemotherapy in man. Blood 1976; 47: 1031-39.
8. To LB, Haylock DN, Kimber RJ, Juttner CA. High levels of circulating haemopoietic stem cells in very early remission from acute nonlymphoblastic leukaemia and their collection and cryopreservation. Br J Haematol 1984; 58: 399-410.
9. Socinski MA, Elias A, Schnipper L, Cannistra SA, Amman KH, Griffin JD. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988; i: 1194-98.
10. Dührsen U, Villeval J-L, Boyd J, Kannourakis G, Morstyn G, Metcalf D. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic cells in cancer patients. Blood 1988; 72: 2074-81.
11. Gianni AM, Siena S, Bregni M, et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; ii: 580-85.
12. Gratwohl A, Hermans J. Indications and donor source of hematopoietic stem cell transplants in Europe 1993: report from the European Group for Blood and Marrow Transplantation (EBMT). Clin Transplant 1995; 9: 355-63.
13. Sheridan WP, Begley CG, Juttner CA, et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640-44.
14. Bensinger W, Singer J, Appelbaum F, et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 1993; 81: 3158-63.
15. Chao NJ, Schriber JR, Grimes K, et al. Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81: 2031-35.
16. Gribben JG, Linch DC, Singer CRJ, et al. Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 1989; 73: 340-44.
17. Philip TH, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non Hodgkin's lymphoma. N Engl J Med 1987; 316: 1493-98.
18. Dreger P, Klöss M, Petersen B, et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995; 86: 3970-78.
19. Dreger P, Marquardt P, Haferlach T, et al. Effective mobilisation of peripheral blood progenitor cells with "Dexa-BEAM" and G-CSF: timing of harvesting and composition of the leukapheresis product. Br J Cancer 1993; 68: 950-57.
20. Haas R, Hohaus S, Ehrhardt R, Goldschmidt H, Witt B, Hunstein W. Mobilization of blood stem cells with recombinant human (rh)G-CSF in patients with hematological malignancies and solid tumours. In: Wunder EW, Henon PR, eds. Peripheral blood stem cell autografts. Berlin: Springer-Verlag, 1993: 155-67.
21. Stahel RA, Jost LM, Cerny T, et al. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol 1994; 12: 1931-38.
22. Gisselbrecht C, Prentice HG, Bacigalupo A, et al. Placebo-controlled phase III trial of lenograstim in bone marrow transplantation. Lancet 1994; 343: 696-700.
23. Schmitz N, Dreger P, Zander AR, et al. Results of a randomized, controlled, multicentre study of recombinant human granulocyte-colony stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant 1995; 15: 261-66.
24. Smith TJ, Hillner BE, Yanovich S, et al. Economic analysis of peripheral blood progenitor cell (PBPC) or autologous bone marrow (ABM) transplant in relapsed Hodgkin disease (HD) and non-Hodgkin lymphoma (NHL). Proc Am Soc Clin Oncol 1995; 14: 314.
25. Haylock DN, To LB, Dowse TL, Juttner CA, Simmons PJ. Ex vivo expansion and maturation of peripheral blood CD34+ cells into the myeloid lineage. Blood 1992; 80: 1405-12.
26. Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994; 369: 565-69.